Compare · ABT vs IMNN
ABT vs IMNN
Side-by-side comparison of Abbott Laboratories (ABT) and Imunon Inc. (IMNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and IMNN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 22804.7x IMNN ($7.7M).
- IMNN has been more active in the news (16 items in the past 4 weeks vs 12 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 0 for IMNN).
- Company
- Abbott Laboratories
- Imunon Inc.
- Price
- -
- -
- Market cap
- $175.37B
- $7.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 16
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest IMNN
- Executive Chairman of Board Tardugno Michael H was granted 4,410 shares, increasing direct ownership by 7% to 64,396 units (SEC Form 4)
- SEC Form 3 filed by new insider Blacher Joshua
- General Counsel and Corp Sec Eylward Susan was granted 920 shares and sold $1,730 worth of shares (920 units at $1.88) (SEC Form 4)
- Chief Medical Officer Faller Douglas Vincent was granted 1,308 shares, increasing direct ownership by 6% to 23,204 units (SEC Form 4)
- President and CEO Lindborg Stacy was granted 2,534 shares, increasing direct ownership by 3% to 76,722 units (SEC Form 4)
- Imunon Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Medical Officer Faller Douglas Vincent was granted 21,896 shares (SEC Form 4)
- General Counsel and Corp Sec Eylward Susan was granted 14,696 shares and sold $20,674 worth of shares (11,800 units at $1.75) (SEC Form 4)
- Executive Chairman of Board Tardugno Michael H was granted 42,519 shares, increasing direct ownership by 243% to 59,986 units (SEC Form 4)
- President and CEO Lindborg Stacy was granted 67,150 shares, increasing direct ownership by 954% to 74,188 units (SEC Form 4)